April 21, 2017

Comtech Telecommunications Corp. (NASDAQ:CMTL) subsidiary get five-year contract value of $42.7 million

Comtech Telecommunications Corp. (NASDAQ:CMTL) announced that during its third quarter of fiscal 2017, its Maryland-based subsidiary, Comtech Mobile Datacom Corporation, which is part of Comtech’s Government Solutions segment, has been awarded a five-year contract, with a not-to-exceed value of $42.7 million, to continue to provide sustainment support for the U.S. Army’s Project Manager Mission Command (PM MC) – Blue Force Tracking (“BFT-1”) program. BFT-1 is a battle command real-time situational awareness and control system.

Comtech Telecommunications Corp. (NASDAQ:CMTL) shares gained 1.62% to $13.84 on Thursday.

Under the new five-year BFT-1 sustainment contract, Comtech will perform engineering services, satellite network operations and program management through a hybrid Firm Fixed Price (FFP)/Time & Materials (T&M) contract with Cost Reimbursement CLINs.

Technical Stock Analysis

Shares outstanding are recorded as 23.55 million and total shares floated are 22.73 million. Current ratio which is the relationship between current assets and current liabilities, indicating the liquidity of a business is calculated as 1.80. Company’s distance from 20 day simple moving average is -0.76% and distance from 50-Day simple moving average is 7.42%.

Best time to invest in stock market is when things are on odd side, and it’s not easy how to pick stocks. By reviewing stock prices from the stock market history of the company and examining its analysts ratings can give an investment picture with updated information of stock which helps investors to make investing decision. Stock has got OUTPERFORM rating from 2 analysts of Thomson Reuters, 2 analysts given HOLD rating to the stock and 0 given UNDERPERFORM rating. Analyst’s mean target price for CMTL is $17.25 while analysts mean recommendation is 2.20.

Comtech Telecommunications Corp. (NASDAQ:CMTL) yearly performance is -34.13% and net profit margin is -1.40%. Annual EPS Growth of past 5 years is -17.10%. The current share price indicates that stock is -40.65% away from its one year high and is moving 47.79% ahead of its 52-week low.

Eli Lilly and Company (NYSE:LLY) and its partner Incyte Corporation INCY recently announced that they have received a Complete Response Letter (CRL) from the FDA regarding the new drug application (NDA) for baricitinib. Lilly was seeking approval of baricitinib for the treatment of moderate-to-severe rheumatoid arthritis (RA) in the U.S. We remind investors that baricitinib was approved in EU in Feb 2017 for the given indication. The drug is to be marketed by the trade name of Olumiant in EU. It was the first JAK inhibitor to receive approval to treat RA in the EU.

On 20 April 2017, Eli Lilly and Company (NYSE:LLY) shares moved to $81.94 after starting the day at $81.19. Stock has got OUTPERFORM rating from 8 analysts of Thomson Reuters, 5 analysts given HOLD rating to the stock and 0 given UNDERPERFORM rating. Analyst’s mean target price for LLY is $88.30 while analysts mean recommendation is 2.00.

At the movement Mohawk Industries, Inc. (NYSE:MHK) is under coverage by number of analysts. Buy rating has been given by 7 analysts to the company stock whereas no analyst given UNDERPERFORM rating to stock and 4 analysts given HOLD rating. The consensus recommendation by Thomson Reuters analysts is Outperform and their mean rating for the stock is 1.85 on scale of 1-5. Analysts mean target price for Mohawk Industries, Inc. (NYSE:MHK) is $252.38 while their mean recommendation is 1.80 (1=Buy, 5=sell).

If we look at stock performance in last active day trading, we see that stock has moved gained 0.88% to end the day at $236.29. The current share price indicate that stock is 0.55% away from its one year high and is moving 34.62% ahead of its 52-week low.

Leave a Reply

Your email address will not be published. Required fields are marked *